Retatrutide: Frequently Asked Questions
FM
Reviewed by Fat Man in the Arena · Updated March 2026
Not medical advice. These answers are for educational purposes based on published research. Full disclaimer.
When will retatrutide be available?
Retatrutide is currently in Phase 3 clinical trials conducted by Eli Lilly. Based on typical regulatory timelines, FDA approval could come in late 2026 or 2027 if Phase 3 results are positive. The compound is not yet available by prescription or through compounding pharmacies.
How does retatrutide compare to semaglutide and tirzepatide?
In Phase 2 data, retatrutide showed 24.2% weight loss at the highest dose over 48 weeks, compared to 14.9% for semaglutide (68 weeks) and 20.9% for tirzepatide (72 weeks). However, direct head-to-head comparisons have not been conducted yet.
Sources
- Triple-Hormone-Receptor Agonist Retatrutide for Obesity (Phase 2) — New England Journal of Medicine (2023) [PubMed]
Weekly peptide research updates
New studies, GLP-1 news, protocol insights, and weight loss data — delivered every week. Free. No spam.